Himalaya Early Access Program
NCT05345678 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2022-12-14
Summary
To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IV administered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab 1500 mg IV Q4W monotherapy in patients with unresectable HCC.
Conditions
Interventions
- DRUG
-
Dose: 1500mg Route: IV
- DRUG
-
Tremelimumab
Dose: 300mg Route: IV
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
NCT06526104 ·Status: RECRUITING ·Phase: PHASE2
-
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
NCT07081633 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
NCT05027425 ·Status: TERMINATED ·Phase: PHASE2
-
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
NCT02519348 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma
NCT05864755 ·Status: RECRUITING ·Phase: PHASE2
-
Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC)
NCT01381211 ·Status: TERMINATED ·Phase: PHASE2
-
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
NCT05809869 ·Status: RECRUITING ·Phase: PHASE2
-
Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab
NCT06796114 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
NCT06911255 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785 ·Status: RECRUITING ·Phase: PHASE3
-
Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure
NCT06045975 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
NCT04430452 ·Status: RECRUITING ·Phase: PHASE2
-
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
NCT04522544 ·Status: RECRUITING ·Phase: PHASE2
-
Tremelimumab With Chemoembolization or Ablation for Liver Cancer
NCT01853618 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
NCT06364007 ·Status: RECRUITING ·Phase: PHASE2
-
Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients
NCT05844046 ·Status: RECRUITING ·Phase: PHASE2
-
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
NCT03638141 ·Status: COMPLETED ·Phase: PHASE2
-
Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma
NCT04183088 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
NCT04567615 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
NCT05044676 ·Status: TERMINATED
-
SIRT With Tremelimumab and Durvalumab for Resectable HCC
NCT05701488 ·Status: RECRUITING ·Phase: PHASE1
-
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
NCT07027436 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
NCT00057382 ·Status: TERMINATED ·Phase: PHASE2/PHASE3